Abstract
Chronic lymphocytic leukemia (CLL) is a type of blood cancer with accumulated abnormal B cells growing out of control in bone marrow, blood and secondary lymphoid organs. It is the most common adult leukemia in the western world and remains incurable . Identification of therapeutic targets and development of effective target therapies are crucial and highly demanding. The well tolerated Bruton’s tyrosine Kinase (BTK) inhibitor, ibrutinib (formally called PCI-32765) , represents one of the most exciting breakthroughs in the field of B cell malignancy therapy. In clinical investigation ibrutinib has been shown to have significant clinical activity against B cell malignancies including CLL and it was recently approved for the treatment of mantle cell lymphoma and CLL . BTK is a critical component of the B cell receptor (BCR) signaling pathway . Beside BTK, other kinases such as IL2-inducible T-cell kinase (ITK) have been identified as targets of ibrutinib . The lack of selectivity of ibrutinib makes it necessary to validate the critical role of BTK in CLL. In a recent study , Woyach and colleagues confirmed the critical function of BTK in the initiation and expansion of CLL and validated BTK as an important target of ibrutinib.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.